Dropbox Inc vs Novavax Inc — how do they compare? Dropbox Inc trades at $34.61 (market cap $7.42B), while Novavax Inc trades at $12.6 (market cap $1.82B). The key difference: Dropbox Inc is far larger — about 4.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Dropbox Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Novavax Inc for 59 Days on average.
| DBX | NVAX | |
|---|---|---|
Market Cap | $7.42B | $1.82B |
Volume | 3,061,580 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $37.74 | $12.56 |
52-Week Low | $22.06 | $6.22 |
Typical Hold Time | 97 Days | 59 Days |
Enterprise Value | $10.29B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% amid bearish technical signals and mixed analyst sentiment. The company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. However, negative shareholder equity and recent insider selling create headwinds. Technical indicators show bearish momentum with support at $32 and resistance at $34.
Outlook remains cautious despite solid fundamentals. The stock faces valuation concerns with a P/E of 18.86 and mixed analyst ratings (37.5% buy, 31.25% hold/sell each). Key risks include stagnant revenue growth, high debt levels, and competitive pressures in cloud storage. The consensus price target of $26.83 suggests potential downside from current levels.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →